These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: New treatment for KS offers options for therapy.
    Journal: AIDS Alert; 1996 Feb; 11(2):21-2. PubMed ID: 11363236.
    Abstract:
    Researchers are still divided as to whether Kaposi's sarcoma (KS), the most common HIV infection complication, is a true cancer or a skin disease resulting from an unknown infectious agent. A comparative trial for KS treatments indicates that Doxil may be more effective than the current standard of care for widespread systemic disease. More studies are necessary before drug superiority can be determined. Doxil is being promoted as superior due to its longer circulating half-life of approximately 50 hours compared to 10 minutes for free (non-liposome) doxorubicin. Detractors question whether the drug's longer half-life allows it to penetrate the tumor. Variations in trial protocols and response assessment indicate further problems in the Doxil trial.
    [Abstract] [Full Text] [Related] [New Search]